Published 15th September 2016

Veryan enrols first patient in MIMICS3D resgistry

MIMICS-3D is a prospective, multicentre, observational registry to evaluate the BioMimics 3D Self-Expanding Stent System in the treatment of peripheral arterial disease. The Registry will evaluate safety, effectiveness and device performance within a real-world clinical population in a minimum of 500 patients across Europe.

The MIMICS-3D Registry PI, Michael Lichtenberg MD (Arnsberg, Germany) commented:

“Having been able to enroll a significant number of patients into the MIMICS-2 IDE Study I am delighted to be the PI of the MIMICS-3D Registry, and particularly pleased to be able to enrol the first patient into the MIMICS-3D Registry. The three studies within the MIMICS programme will provide a combined database of clinical experience that I expect to provide significant validation of the unique helical shape of BioMimics 3D and the clinical benefits of swirling flow.”

Chas Taylor, Veryan CEO commented:

“This milestone is another significant step in the Veryan clinical programme. Veryan is committed to seeking high quality, compelling clinical data for our BioMimics 3D stent. We have been overwhelmed by the enthusiasm shown across Europe by clinicians wishing to participate in the MIMICS-3D Registry which illustrates the growing understanding of, and belief in, the clinical benefits of swirling flow.”

Read Veryan's statement

Learn more about BioMimics3D in Veryan's website

Press contacts